We are live on ! Find out more
RVMD icon

Revolution Medicines
RVMD

135 hedge funds and large institutions have $1.49B invested in Revolution Medicines in 2022 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 42 increasing their positions, 40 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

144% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 9

11% more funds holding in top 10

Funds holding in top 10: 9 → 10 (+1)

7% more funds holding

Funds holding: 126 → 135 (+9)

2.62% more ownership

Funds ownership: 100.36% → 102.98% (+2.6%)

5% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 40

21% less capital invested

Capital invested by funds: $1.89B → $1.49B (-$397M)

99% less call options, than puts

Call options by funds: $6K | Put options by funds: $488K

Holders
135
Holders Change
+9
Holders Change %
+7.14%
% of All Funds
2.27%
Holding in Top 10
10
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+11.11%
% of All Funds
0.17%
New
22
Increased
42
Reduced
40
Closed
9
Calls
$6K
Puts
$488K
Net Calls
-$482K
Net Calls Change
-$2.53M

Top Buyers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
+$58.5M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$40.6M
3
APM
Avidity Partners Management
Texas
+$25.8M
4
CG
Column Group
California
+$20.4M
5
JP Morgan Chase
JP Morgan Chase
New York
+$9.97M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$54.5M
2
WP
Woodline Partners
California
-$40.2M
3
Capital World Investors
Capital World Investors
California
-$31.3M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$9.56M
5
TGI
TRV GP III
Massachusetts
-$8.17M
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$12.5M +$181K +9,315 +1%
Dimensional Fund Advisors
27
Dimensional Fund Advisors
Texas
$12.3M +$2.96M +151,921 +32%
CS
28
Candriam SCA
Luxembourg
$10.8M +$2.36M +121,051 +28%
Norges Bank
29
Norges Bank
Norway
$9.59M +$379K +19,456 +4%
Charles Schwab
30
Charles Schwab
California
$8.66M +$3.72K +191 +0%
Bessemer Group
31
Bessemer Group
New Jersey
$8.54M – – –
PAMP
32
Polar Asset Management Partners
Ontario, Canada
$6.81M +$6.8M +349,500 New
TP
33
Thunderbird Partners
United Kingdom
$6.71M +$6.7M +344,324 New
DCM
34
DAFNA Capital Management
California
$5.84M +$1.32M +67,684 +29%
WP
35
Woodline Partners
California
$5.14M -$40.2M -2,067,596 -89%
Millennium Management
36
Millennium Management
New York
$4.98M +$4.51M +231,670 +975%
Morgan Stanley
37
Morgan Stanley
New York
$4.72M +$1.06M +54,261 +29%
BBA
38
Baker Bros. Advisors
New York
$4.33M – – –
N
39
Nuveen
North Carolina
$4.12M +$49.1K +2,524 +1%
Bank of New York Mellon
40
Bank of New York Mellon
New York
$3.86M -$1.24M -63,797 -24%
AllianceBernstein
41
AllianceBernstein
Tennessee
$3.85M -$552K -28,371 -13%
Citadel Advisors
42
Citadel Advisors
Florida
$3.84M +$2.54M +130,258 +195%
TLP
43
Tri Locum Partners
New York
$2.89M -$428K -22,002 -13%
MB
44
MPM BioImpact
Massachusetts
$2.85M – – –
Voloridge Investment Management
45
Voloridge Investment Management
Florida
$2.19M +$376K +19,309 +21%
Citigroup
46
Citigroup
New York
$2.13M +$1.58M +80,987 +284%
Two Sigma Advisers
47
Two Sigma Advisers
New York
$2.09M -$444K -22,800 -18%
Bank of America
48
Bank of America
North Carolina
$2.06M -$2.05M -105,117 -50%
Swiss National Bank
49
Swiss National Bank
Switzerland
$2.03M -$175K -9,000 -8%
Rafferty Asset Management
50
Rafferty Asset Management
New York
$2.01M -$888K -45,621 -31%
1
2
3 4 5

RVMD Hedge Fund Activity: Q2 2022 in Review

135 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Revolution Medicines (RVMD) for Q2 2022, worth a combined $1.49B — down 21% from $1.89B a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new RVMD positions and 9 closed out — a net gain of 13 holders — while 42 added to existing stakes and 40 trimmed.

The largest buyer was EcoR1 Capital, adding an estimated $58.5M. The largest seller was Fidelity Investments, cutting an estimated $54.5M.

  • 135 institutional investors held Revolution Medicines (RVMD) as of Q2 2022, up from 126 in Q1 2022.
  • Funds reported $1.49B of Revolution Medicines stock for Q2 2022, down 21% quarter-over-quarter.
  • 22 funds opened new Revolution Medicines positions in Q2 2022 and 9 closed out, a net change of +13 holders.
  • The largest Revolution Medicines buyer in Q2 2022 was EcoR1 Capital, an estimated $58.5M added.
  • The largest Revolution Medicines seller in Q2 2022 was Fidelity Investments, an estimated $54.5M sold.

Based on aggregated 13F filings for Q2 2022.